Back

Bridging the gap: real-world eligibility for lipoprotein(a)-targeted therapies in chronic and acute coronary syndrome

28 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Lipid lowering (1) Drug therapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Eva Steinacher

Medical University of Vienna, Vienna (Austria)

6 More presentations in this session

Presentation thumbnail
LDL-C target achievement does not equal risk resolution after ACS: residual atherogenic and inflammatory burden despite maximal oral triple lipid therapy
Doctor K. Mahajan (Mandi, IN)
Abstract Slides
Presentation thumbnail
Association of LDL-C/ApoB ratio with pathogenic variants in familial hypercholesterolemia
Doctor F. Wollmann (Wien, AT)
Abstract Slides
Presentation thumbnail
Real-world efficacy and tolerability of lipid-lowering therapy in children with monogenic familial hypercholesterolemia in primary care
Mr R. Schmieder (Munich, DE)
Abstract Slides
Presentation thumbnail
Association of apolipoprotein B and lipoprotein(a) with severe atherosclerotic cardiovascular disease in patients with acute coronary syndrome: the modifying effect of prior lipid-lowering therapy.
Mr A. Meseguer Hernandez (Cartagena, ES)
Abstract Slides
Presentation thumbnail
Elective coronary revascularisation represents an unutilised opportunity to optimise lipid management: results from a multicentre observational cohort
Miss M. van den Bogaart (Amsterdam, NL)
Abstract Slides

Access the full session

Session thumbnail
Lipid lowering (1)

The Event

Event poster

ESC Congress 2026

28 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Impact of lipoprotein(a) as a residual risk on long-term cardiovascular outcomes in patients with acute coronary syndrome treated with statin
27 August 2021
thumbnail
Congress Presentation
The current LDL-C target <1.4mmol/l of the ESC is achieved in less than 16% of patients with Coronary Heart Disease despite effective lipid-lowering therapy: Data from the LLT-R registry
28 August 2020
thumbnail
Congress Session
Lp(a): from causality to therapy
28 August 2022
thumbnail
Congress Presentation
Characteristics of patients with a lipoprotein(a) assessment - a health insurance claims database analysis
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources